Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor
    1.
    发明申请
    Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses therefor 审中-公开
    小分子18636,2446,43238,1983,52881,29898,45449,50289,52872和26908分子及其用途

    公开(公告)号:US20070015201A1

    公开(公告)日:2007-01-18

    申请号:US11522789

    申请日:2006-09-18

    摘要: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供分离的核酸分子,命名为18636,2466,43238,1983,52881,29898,45449,50289,52872和26908核酸分子。 本发明还提供反义核酸分子,含有18636,2466,43238,1983,52881,29898,45449,502892,5282和26908核酸分子的重组表达载体,已经引入表达载体的宿主细胞和非人转基因 引入或破坏18636,2466,43238,1983,52881,2398,45449,50289,52872或26908基因的动物。 本发明还进一步提供了分离的18636,2466,43238,1983,52881,2398,45449,50289,52872或26908蛋白,融合蛋白,抗原肽和抗-18636,2466,43238,1983,52881,29898,45449,50289 ,52872或26908抗体。 还提供了利用本发明组合物的诊断和治疗方法。

    Novel nucleic acid sequences encoding G-protein coupled receptors
    2.
    发明申请
    Novel nucleic acid sequences encoding G-protein coupled receptors 审中-公开
    编码G蛋白偶联受体的新型核酸序列

    公开(公告)号:US20060275866A1

    公开(公告)日:2006-12-07

    申请号:US11268745

    申请日:2005-11-07

    CPC分类号: C07K14/705

    摘要: The invention provides isolated nucleic acids molecules, designated 2871, 14926, 44576, 23992, 1983, 52881, 2398, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor family members that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 proteins, fusion proteins, antigenic peptides and anti-2871, 14926, 44576, 23992, 1983, 52881, 2398, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供分离的核酸分子,命名为2871,14926,4457,239992,1983,52881,2988和52872核酸分子,其编码编码新多肽的新型G蛋白偶联受体家族成员。 本发明还提供反义核酸分子,含有2871,14926,4576,23992,1983,52881,2398或52872核酸分子的重组表达载体,已经引入了表达载体的宿主细胞,以及非人转基因动物,其中 已经引入或破坏了2871,14926,44576,23992,1983,52881,2398或52872基因。 本发明还进一步提供了分离的2871,14926,4457,239992,1983,52881,2398或52872蛋白质,融合蛋白,抗原肽和抗-2871,14926,4457,23992,1983,52881,29898或52872抗体。 还提供了利用本发明组合物的诊断方法。

    43239, a novel GPCR-like molecule and uses thereof
    7.
    发明申请
    43239, a novel GPCR-like molecule and uses thereof 审中-公开
    43239,一种新型的GPCR样分子及其用途

    公开(公告)号:US20050089925A1

    公开(公告)日:2005-04-28

    申请号:US10435828

    申请日:2003-05-12

    CPC分类号: C07K14/705 A61K38/00

    摘要: Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译: 公开了新的GPCR样多肽,蛋白质和核酸分子。 除了分离的全长GPCR样蛋白之外,本发明还提供了分离的GPCR样融合蛋白,抗原肽和抗GPCR样抗体。 本发明还提供了GPCR样核酸分子,含有本发明的核酸分子的重组表达载体,已经引入了表达载体的宿主细胞和其中已经导入或破坏了GPCR样基因的非人转基因动物 。 还提供了利用本发明组合物的诊断,筛选和治疗方法。

    Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
    9.
    发明申请
    Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor 审中-公开
    小分子18607,15603,69318,12303,48000,52202,5333,38554,57301,58324,55063,52991,59914,59921和33751分子及其用途

    公开(公告)号:US20090226448A1

    公开(公告)日:2009-09-10

    申请号:US12381747

    申请日:2009-03-16

    CPC分类号: C07K14/705 A61K38/00

    摘要: The invention provides isolated nucleic acids molecules, designated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 gene has been introduced or disrupted. The invention still further provides isolated 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 proteins, fusion proteins, antigenic peptides and anti-18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 or 33751 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供分离的核酸分子,命名为18607,15603,69318,12303,48000,52920,5433,38554,57301,58324,55063,52991,59914,59921和33751核酸分子。 本发明还提供反义核酸分子,包含18607,15603,69318,12303,48000,52920,5433,38554,57301,58324,55063,52991,59914,59921和33751核酸分子的重组表达载体,其中宿主细胞 已经引入了表达载体,并且已导入或破坏其中18607,15603,69318,12303,48000,523020,5433,35554,57301,58324,55063,52991,59914,59921或33751基因的非人转基因动物。 本发明还进一步提供了分离的18607,15603,69318,12303,48000,5920,5433,38554,57301,58324,55063,52991,59914,59921或33751蛋白,融合蛋白,抗原肽和抗-18607,15603,69318 ,12303,48000,5920,5433,38554,57301,58324,55063,52991,59914,59921或33751抗体。 还提供了利用本发明组合物的诊断和治疗方法。

    Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
    10.
    发明申请
    Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules 审中-公开
    使用1435,549,34021,44099,25278,641,260,55089,21407,42032,4656,52553,302,323,12303,985,13237,13601,18926,318,2058或用于治疗泌尿系统疾病的方法和组合物或 6351分子

    公开(公告)号:US20060088881A1

    公开(公告)日:2006-04-27

    申请号:US11302678

    申请日:2005-12-14

    IPC分类号: C12Q1/68 G01N33/53

    CPC分类号: C12Q1/6883 C12Q2600/158

    摘要: The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 and 6351 genes in tissues relating to urological disorders, relative to their expression in normal, or non-urological disorders, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

    摘要翻译: 本发明涉及诊断和治疗泌尿系统疾病或泌尿系统疾病的方法。 具体而言,本发明鉴别1435,549,34021,44099,25278,641,260,55089,21407,42032,4656,65353,302,232,12303,985,13237,13601,18926,318的差异表达, 相对于其在正常或非泌尿系统疾病中的表达和/或响应于与泌尿系统疾病相关的操作,与泌尿系统疾病相关的组织中的2058和6351个基因。 本发明描述了各种泌尿系统疾病的诊断评估和预后的方法,以及用于鉴定表现出这种病症倾向的受试者。 本发明还提供了鉴定能够调节泌尿系统疾病或泌尿系统疾病的化合物的方法。 本发明还提供了用于鉴定和治疗性使用化合物作为泌尿系统疾病治疗的方法。